These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11873630)

  • 21. HLA-G truncated isoforms can substitute for HLA-G1 in fetal survival.
    Menier C; Riteau B; Dausset J; Carosella ED; Rouas-Freiss N
    Hum Immunol; 2000 Nov; 61(11):1118-25. PubMed ID: 11137216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is antigen presentation the primary function of HLA-G?
    Le Bouteiller P; Solier C
    Microbes Infect; 2001 Apr; 3(4):323-32. PubMed ID: 11334750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HLA-G and local placental immunity].
    Le Bouteiller P
    Gynecol Obstet Fertil; 2003 Sep; 31(9):782-5. PubMed ID: 14499728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes.
    Le Gal FA; Riteau B; Sedlik C; Khalil-Daher I; Menier C; Dausset J; Guillet JG; Carosella ED; Rouas-Freiss N
    Int Immunol; 1999 Aug; 11(8):1351-6. PubMed ID: 10421792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis.
    Riteau B; Rouas-Freiss N; Menier C; Paul P; Dausset J; Carosella ED
    J Immunol; 2001 Apr; 166(8):5018-26. PubMed ID: 11290782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA-G suppresses proliferation of CD4(+) T-lymphocytes.
    Bainbridge DR; Ellis SA; Sargent IL
    J Reprod Immunol; 2000 Aug; 48(1):17-26. PubMed ID: 10996380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients.
    Le Rond S; Le Maoult J; Créput C; Menier C; Deschamps M; Le Friec G; Amiot L; Durrbach A; Dausset J; Carosella ED; Rouas-Freiss N
    Eur J Immunol; 2004 Mar; 34(3):649-660. PubMed ID: 14991594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells.
    Pazmany L; Mandelboim O; Valés-Gómez M; Davis DM; Reyburn HT; Strominger JL
    Science; 1996 Nov; 274(5288):792-5. PubMed ID: 8864122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunotolerance role of HLA-G.
    Rouas-Freiss N; Khalil-Daher I; Riteau B; Menier C; Paul P; Dausset J; Carosella ED
    Semin Cancer Biol; 1999 Feb; 9(1):3-12. PubMed ID: 10092545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies.
    Bukur J; Seliger B
    Semin Cancer Biol; 2003 Oct; 13(5):353-9. PubMed ID: 14708715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-G expression in human melanoma cells: protection from NK cytolysis.
    Adrián Cabestré F; Moreau P; Riteau B; Ibrahim EC; Le Danff C; Dausset J; Rouas-Freiss N; Carosella ED; Paul P
    J Reprod Immunol; 1999 Jul; 43(2):183-93. PubMed ID: 10479054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response.
    Kapasi K; Albert SE; Yie S; Zavazava N; Librach CL
    Immunology; 2000 Oct; 101(2):191-200. PubMed ID: 11012772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
    Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
    Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA-G and HLA-E: fundamental and pathophysiological aspects.
    Carosella ED; Paul P; Moreau P; Rouas-Freiss N
    Immunol Today; 2000 Nov; 21(11):532-4. PubMed ID: 11221681
    [No Abstract]   [Full Text] [Related]  

  • 35. Soluble HLA-G: Are they clinically relevant?
    Pistoia V; Morandi F; Wang X; Ferrone S
    Semin Cancer Biol; 2007 Dec; 17(6):469-79. PubMed ID: 17825579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-G polymorphisms and molecule function--questions and more questions--a review.
    van der Ven K; Pfeiffer K; Skrablin S
    Placenta; 2000; 21 Suppl A():S86-92. PubMed ID: 10831130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stranger in a strange land.
    Hunt JS
    Immunol Rev; 2006 Oct; 213():36-47. PubMed ID: 16972895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HLA-G in organ transplantation].
    Le Maoult J; Rouas-Freiss N; Le Discorde M; Moreau P; Carosella ED
    Pathol Biol (Paris); 2004 Mar; 52(2):97-103. PubMed ID: 15001239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
    Puppo F; Contini P; Ghio M; Indiveri F
    ScientificWorldJournal; 2002 Feb; 2():421-3. PubMed ID: 12806026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.